MedTrace Logo

First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer

NCT03873883 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2024-09-19

No results posted yet for this study

Summary

Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

EOS100850

Oral administration

DRUG

Pembrolizumab

IV Infusion

DRUG

Chemotherapy

Standard of Care IV Infusion

Sponsors & Collaborators

  • iTeos Belgium SA

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • iTeos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Iteos Clinical Trials · iTeos Belgium SA

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-05
Primary Completion
2024-05-28
Completion
2024-05-28
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03873883 on ClinicalTrials.gov